Assessing Pharma Mar (BME:PHM) Valuation After BBB Credit Rating Upgrade

Pharma Mar (BME:PHM) just received a long term credit rating upgrade to BBB with a stable outlook, a shift that could influence how you view its funding options and growth capacity.

See our latest analysis for Pharma Mar.

The rating upgrade lands at a time when momentum in the share price is already strong, with a 30 day share price return of 17.97% and a year to date share price return of 21.60%. The 3 year total shareholder return of 130.23% points to a materially different experience for longer term holders than the 5 year total shareholder return of 5.32%.

If this kind of credit driven story has your attention, it can be a good moment to widen your watchlist and check out 97 top founder-led companies

With the stock trading at €92.90 and sitting about 17% below one intrinsic value estimate and 12% below the average analyst target, you have to ask: is there still undervaluation here, or is the market already pricing in future growth?

Preferred P/E of 21.5x: Is it justified?

On a P/E of 21.5x, Pharma Mar screens as expensive against the European biotech sector average of 15.2x, even though the shares sit at €92.90.

P/E compares the current share price to earnings per share, so a higher multiple usually reflects the market placing a richer price on each euro of profit. For a biopharma group with meaningful oncology exposure and earnings on the board, that kind of premium often comes down to what investors think about the durability and growth profile of those profits.

Here, the picture is mixed. The 21.5x P/E is lower than both the estimated fair P/E of 31.7x and the peer average of 31.3x. This suggests room for the multiple to move closer to levels implied by that fair ratio if earnings forecasts and cash flow expectations play out as currently modelled. At the same time, the stock still trades on a higher multiple than the broader European biotech group, which points to the market already baking in stronger profitability and growth than the typical peer.

Against this backdrop, the 21.5x P/E sits at a kind of middle ground, above sector but below the level regression based models suggest could be justified if earnings and cash flows track current expectations. In other words, the market appears to be giving Pharma Mar some credit for its profile, but not fully reaching the valuation level implied by the fair P/E estimate.

Explore the SWS fair ratio for Pharma Mar.

Result: Price-to-earnings of 21.5x (ABOUT RIGHT)

However, this hinges on continued success from a concentrated oncology portfolio and late stage trials. Setbacks or weaker than expected revenue of €221.39m could quickly test that valuation.

Find out about the key risks to this Pharma Mar narrative.

Another view on value: SWS DCF model

While the 21.5x P/E suggests the share price is roughly in line with what earnings might justify, the SWS DCF model points in a different direction. On that framework, Pharma Mar at €92.90 sits below an estimated future cash flow value of €111.79, which frames the current price as undervalued based on cash flows rather than earnings multiples alone. So which lens do you trust more when both are sending slightly different signals?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pharma Mar for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 231 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The set up may look promising, but the only view that matters is yours. Move quickly, review the underlying numbers and weigh the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Pharma Mar is on your radar, do not stop there. Use this moment to actively scan for other opportunities that could fit your style and risk tolerance.

• Target potential mispricings by reviewing companies in the 231 high quality undervalued stocks, where solid fundamentals may not yet be fully reflected in the share price.
• Prioritise resilience by focusing on companies featured in the 300 resilient stocks with low risk scores, aiming to keep downside in check while staying invested.
• Hunt for quality that flies under the radar through the screener containing 574 high quality undiscovered gems, so you are not only reacting to stories already crowded with attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com